CoChat

Adding Insulin Glargine Versus Rosiglitazone

Open access
Vinik, Aaron I., Zhang, Quanwu · 2007 · Diabetes Care
Cited by 63

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—We sought to assess health-related quality of life (HRQOL) in patients with type 2 diabetes treated with insulin glargine or rosiglitazone as add-on therapy to sulfonylurea plus metformin. RESEARCH DESIGN AND METHODS—HRQOL was evaluated in 217 subjects uncontrolled with sulfonylurea plus metformin, enrolled in a 24-week, multicenter, randomized, open-label, parallel-group trial of add-on insulin glargine versus rosiglitazone. A 40-item, self-administered questionnaire at baseline and at weeks 2, 6, 12, 18, and 24 was given, including the 34-item Diabetes Symptom Checklist-Revised (DSC-R), a 5-item mental health scale from the 36-item Short-Form Health Survey (SF-36), and a single-item health rating from the SF-36. These assessments do not specify route of therapy. RESULTS—Both treatment groups showed similar improvements in glycemic control from baseline to week 24 (change in A1C: −1.66% in the insulin glargine group, −1.51% in the rosiglitazone group, P = 0.1446). Both groups also showed improvement in HRQOL, although subjects treated with insulin glargine experienced significantly greater improvements compared with rosiglitazone in the DSC-R total symptom score (P = 0.005), total symptom distress score (P = 0.03), individual domain scores for mood symptoms (P = 0.007), ophthalmologic symptoms (P = 0.007), ophthalmologic distress (P = 0.013), fatigue distress (P = 0.033), and SF-36 perception of general health (P = 0.047). CONCLUSIONS—Although addition of insulin glargine and rosiglitazone achieved comparable improvements in glycemic control, insulin glargine was associated with greater improvements in HRQOL, indicating that other factors (e.g., safety profile and nonglycemic actions) may further enhance HRQOL in patients with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc06-1712

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 17

  1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986, 1993 · DOI · Paper page
  2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998 · DOI · Paper page
  3. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the U.K. Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330–336, 2002 · DOI · Paper page
  4. Hunt LM, Valenzuela MA, Pugh JA: NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 20:292–298, 1997 · DOI · Paper page
  5. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 (Suppl. 3):S18–S24, 2002 · DOI · Paper page
  6. Goddijn PPM, Bilo HJG, Feskens EJM, Groeniert KH, van der Zee KI, Meyboom-de Jong B: Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control. Diabet Med 16:23–30, 1999 · DOI
  7. Pibernik-Okanović M, Szabo S, Metelko Ž: Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics 14:201–207, 1998 · DOI
  8. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M: The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin 20:1703–1710, 2004 · DOI
  9. de Sonnaville JJJ, Snoek FJ, Colly LP, Devillé W, Wijkel D, Heine RJ: Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 21:919–924, 1998 · DOI
  10. Davis TME, Clifford RM, Davis WA: Effect of insulin therapy on quality of life in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 52:63–71, 2001 · DOI
  11. U.K. Prospective Diabetes Study Group: Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22:1125–1136, 1999 · DOI · Paper page
  12. Strowig SM, Avilés-Santa ML, Raskin P: Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27:1577–1583, 2004 · DOI
  13. LeRoith D, Fonseca V, Vinik A: Metabolic memory in diabetes-focus on insulin. Diabete Metab Res Rev 21:85–90, 2005 · DOI · Paper page
  14. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G, on behalf of the Insulin Glargine 4014 Study Investigators: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care 29:554–559, 2006 · DOI · Paper page
  15. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 11:253–261, 1994 · DOI · Paper page
  16. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483, 1992 · DOI · Paper page
  17. Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI: The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 7:497–508, 2005 · DOI · Paper page

Cited by

See all 63

Metadata

Authors
Vinik, A. I., & Zhang, Q.
Venue
Diabetes Care
Published
2007-04-01
Volume
30
Issue
4
Pages
795-800
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2046141503
Cited by
63
References
2
FWCI
7.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.